Target：RERG

Gene Name：RERG

Protein Name：Ras-related and estrogen-regulated growth inhibitor

Human Gene Id：85004

Human Swiss Prot No：Q96A58

Mouse Gene Id：232441

Mouse Swiss Prot No：Q8R367

Immunogen：Synthesized peptide derived from RERG . at AA range: 70-150

Specificity：RERG Polyclonal Antibody detects endogenous levels of RERG protein.

Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：IHC 1:100 - 1:300. ELISA: 1:5000.. IF 1:50-200

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Other Name：RERG;Ras-related and estrogen-regulated growth inhibitor

Molecular Weight(Da)：23kD

Background： RERG, a member of the RAS superfamily of GTPases, inhibits cell proliferation and tumor formation (Finlin et al., 2001 [PubMed 11533059]).[supplied by OMIM, Mar 2009],

Function：disease:Loss of RERG expression may contribute to tumorigenesis in breast. RERG expression is decreased or lost in a significant proportion of primary breast tumors with poor clinical prognosis. High expression of RERG correlates with long relapse-free survival times.,function:Binds GDP/GTP and possesses intrinsic GTPase activity. Has higher affinity for GDP than for GTP. In cell lines overexpression leads to a reduction in the rate of proliferation, colony formation and in tumorigenic potential.,induction:Up-regulated by estradiol. Down-regulated by tamoxifen.,similarity:Belongs to the small GTPase superfamily. Ras family.,tissue specificity:Detected in heart, brain, placenta, lung, liver, skin, kidney and pancreas. Detected in estrogen receptor-positive breast-derived cell lines, but not in estrogen receptor-negative cell lines.,

Subcellular Location：Cytoplasm .

Expression：Detected in heart, brain, placenta, lung, liver, skin, kidney and pancreas. Detected in estrogen receptor-positive breast-derived cell lines, but not in estrogen receptor-negative cell lines. Expression is decreased or lost in a significant proportion of primary breast tumors with poor clinical prognosis.